Moshe Levy, MD
Medical Oncology · Dallas, TXNPI 1518059807
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,758,438 of the $5,078,640 with a category attached, or 74.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.1%. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,548 payments — averaging $1431.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$1.1M
- Takeda Pharmaceuticals U.S.A., Inc.$472K
- E.r. Squibb & Sons, L.L.C.$372K
- Incyte Corporation$358K
- Beigene USA, Inc.$313K
- AbbVie$252K
- plus $2.2M from 54 others
Across 1,222 payments — averaging $12,035 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$7.5M
- Novartis$3.5M
- Pfizer$1.2M
- Karyopharm Therapeutics Inc.$401K
- Acerta Pharma LLC$214K
- AbbVie$186K
- plus $1.7M from 28 others
What the payments were for
- Consulting fees$842,79017%
- Speaking & faculty fees$3,758,43874%
- Travel & lodging$425,7108%
- Food & beverage$51,6901%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADCETRIS$1,148,559
- MONJUVI$352,114
- BRUKINSA$347,854
- ICLUSIG$315,254
- DOPTELET$236,044
- Reblozyl$196,723
- Venclexta$183,531
- XPOVIO$170,814
- CALQUENCE$161,116
- Kyprolis$144,453
- NINLARO$128,558
- TAZVERIK$118,451
- Vonjo$109,784
- REVUFORJ$103,395
- Yescarta$86,607
- EPKINLY$83,290
- Pomalyst$74,515
- Revlimid$64,673
- BLENREP$63,564
- DARZALEX$60,571
How this compares
$5,078,640 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 120 | $1,747,075 |
| CalquenceAcalabrutinib Maleate | 41 | $546,833 |
| PomalystPomalidomide | 25 | $436,394 |
| RevlimidLenalidomide | 22 | $376,736 |
| JakafiRuxolitinib Phosphate | 22 | $360,333 |
| NinlaroIxazomib Citrate | 27 | $346,841 |
| VenclextaVenetoclax | 35 | $285,039 |
| SprycelDasatinib | 11 | $197,496 |
| EliquisApixaban | 36 | $42,052 |
| XareltoRivaroxaban | 32 | $30,277 |
| ValacyclovirValacyclovir Hcl | 40 | $1,791 |
| Entecavir | 12 | $1,089 |
| Hydroxyurea | 31 | $779 |
| Dexamethasone | 36 | $446 |
| Allopurinol | 43 | $364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $313,075 | $1,747,075120 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $371,917 | $633,89036 claims |
| AstraZenecaCalquence | $171,134 | $546,83341 claims |
| Bristol Myers SquibbRevlimid | $134,105 | $376,73622 claims |
| Incyte CorporationJakafi | $357,975 | $360,33322 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $472,082 | $346,84127 claims |
| AbbVieVenclexta | $251,587 | $285,03935 claims |
| PfizerEliquis | $45,212 | $42,05236 claims |
| Johnson & JohnsonXarelto | $92,785 | $30,27732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
- Kartik KonduriDallas$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.